Estelle Marrer-Berger

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 4

Top Topics

Genetic Diversity

Induced Pluripotent Stem Cells

Top Venues

Clinical pharmacology and therapeutics

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Sara Belli, Maria Amann, Lucy Hutchinson, Laurène Pousse, Afsaneh Abdolzade-Bavil, Nicole Justies, Bjoern Jacobsen, Corinne Ploix, Eleni Tselempi, Vinko Tosevski, Hans Koll, Gabriel Schnetzler, Christophe Boetsch, Estelle Marrer-Berger
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting Antibody. Clinical pharmacology and therapeutics 116 (3) (2024)
Sara Belli, Maria Amann, Lucy Hutchinson, Laurène Pousse, Afsaneh Abdolzade-Bavil, Nicole Justies, Bjoern Jacobsen, Corinne Ploix, Eleni Tselempi, Vinko Tosevski, Hans Koll, Gabriel Schnetzler, Christophe Boetsch, Estelle Marrer-Berger
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting Antibody. Clinical pharmacology and therapeutics (2024)
Arthur J Van De Vyver, Estelle Marrer-Berger, Ken Wang, Thorsten Lehr, Antje-Christine Walz
Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk? Clinical cancer research : an official journal of the American Association for Cancer Research 27 (22) (2021)
Frank R Brennan, Joy Cavagnaro, Kathleen McKeever, Patricia C Ryan, Melissa M Schutten, John Vahle, Gerhard F Weinbauer, Estelle Marrer-Berger, Lauren E Black
Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment. mAbs 10 (1) (2017)